🟢 Rocket Pharmaceuticals is trading 5% up today after FDA confirms continued RP-A501 trial enrollment

Rocket Pharmaceuticals is trading 5.03% up now at $3.65 after the FDA confirmed continued enrollment and dosing in its pivotal RP-A501 Phase 2 Danon disease trial.

• The agency accepted a 12-patient pivotal cohort and 12-month co-primary endpoints, reducing regulatory uncertainty.
• The move is also supported by a broader biotech rally and stronger risk appetite across U.S. markets.